Enantiomerically pure .beta.-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
AssigneeEmory University
InventorRaymond F. Schinazi
Life of this patent
Estimating the term…
Abstract
A method and composition for the treatment of humans infected with HBV that includes the administration of an HBV treatment amount of a .beta.-dioxolanyl purine nucleoside of the formula: ##STR1## wherein R is OH, Cl, NH.sub.2, or H, or a pharmaceutically acceptable salt or derivative of the compound, optionally in a pharmaceutically acceptable carrier or diluent.
Claims12
A method for the treatment of HBV infection in a human or other host animal, comprising administering an HBV treatment amount of an enantiomerically pure .beta.-D-dioxolanyl nucleoside of the structure:
- ##STR3## wherein R is OH, and X is selected from the group consisting of hydrogen, alkyl, acyl, monophosphate, diphosphate, and triphosphate, or its pharmaceutically acceptable salt, and wherein the compound is at least 95% free of the corresponding .beta.-L enantiomer.
A method for the treatment of HBV infection in a human or other host animal, comprising administering an HBV treatment amount of an enantiomerically pure .beta.-D-dioxolanyl nucleoside of the structure:
- ##STR4## wherein R is NH.sub.2, and X is selected from the group consisting of hydrogen, alkyl, acyl, monophosphate, diphosphate, and triphosphate, or its pharmaceutically acceptable salt, and wherein the compound is at least 95% free of the corresponding .beta.-L enantiomer.
A method for the treatment of HBV infection in a human or other host animal, comprising administering an HBV treatment amount of an enantiomerically pure .beta.-D-dioxolanyl nucleoside of the structure:
- ##STR5## wherein R is H or Cl, and X is selected from the group consisting of hydrogen, alkyl, acyl, monophosphate, diphosphate, and triphosphate, or its pharmaceutically acceptable salt, and wherein the compound is at least 95% free of the corresponding .beta.-L enantiomer.
A method for the treatment of HBV infection in a human or other host animal, comprising administering an HBV treatment amount of the racemic mixture of a .beta.-dioxolanyl nucleoside of the structure:
- ##STR6## wherein R is OH, and X is selected from the group consisting of hydrogen, alkyl, acyl, monophosphate, diphosphate, and triphosphate, or its pharmaceutically acceptable salt.
A method for the treatment of HBV infection in a human or other host animal, comprising administering an HBV treatment amount of the racemic mixture of a .beta.-dioxolanyl nucleoside of the structure:
- ##STR7## wherein R is NH.sub.2, and X is selected from the group consisting of hydrogen, alkyl, acyl, monophosphate, diphosphate, and triphosphate, or its pharmaceutically acceptable salt.
A method for the treatment of HBV infection in a human or other host animal, comprising administering an HBV treatment amount of the racemic mixture of a .beta.-dioxolanyl nucleoside of the structure:
- ##STR8## wherein R is H or Cl, and X is selected trom the group consisting of hydrogen, alkyl, acyl, monophosphate, diphosphate, and triphosphate, or its pharmaceutically acceptable salt.
Dependencies are inferred from the claim text.